General Information of Drug Combination (ID: DC0TCKI)

Drug Combination Name
Minocycline Colistimethate
Indication
Disease Entry Status REF
Acinetobacter Infections Phase 4 [1]
Component Drugs Minocycline   DMVN5OH Colistimethate   DMZ9BMU
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Minocycline
Disease Entry ICD 11 Status REF
Acne vulgaris ED80 Approved [2]
Actinomycosis N.A. Approved [2]
Acute gonococcal cervicitis N.A. Approved [2]
Bacterial infection 1A00-1C4Z Approved [3]
Bartonellosis N.A. Approved [2]
Bronchitis CA20 Approved [2]
Brucellosis N.A. Approved [2]
Chancroid N.A. Approved [2]
Listeriosis N.A. Approved [2]
Lymphogranuloma venereum N.A. Approved [2]
Ornithosis N.A. Approved [2]
Periodontitis DA0C Approved [2]
Pneumonia CA40 Approved [2]
Q fever N.A. Approved [2]
Relapsing fever N.A. Approved [2]
Rickettsialpox N.A. Approved [2]
Rocky mountain spotted fever N.A. Approved [2]
Syphilis N.A. Approved [2]
Trachoma N.A. Approved [2]
Tularemia 1B94 Approved [2]
Typhus N.A. Approved [2]
Urinary tract infection GC08 Approved [2]
Yaws N.A. Approved [2]
Rosacea ED90.0 Phase 2 [4]
Plague N.A. Investigative [2]
Sinusitis CA0A.Z Investigative [2]
Vibrio cholerae infection 1A00 Investigative [2]
Minocycline Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Staphylococcus 30S ribosomal subunit (Stap-coc pbp2) TTQ8KVI F4NA87_STAAU Binder [6]
------------------------------------------------------------------------------------
Minocycline Interacts with 1 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Increases ADR [7]
------------------------------------------------------------------------------------
Indication(s) of Colistimethate
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Approved [5]
Colistimethate Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Bacterial Dihydropteroate synthetase (Bact folP) TT4ILYC DHPS_ECOLI Binder [8]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT05586815) Efficacy of Colistin Monotherapy Versus Colistin Plus Minocycline for Carbapenem-Resistant A. Baumannii Infection
2 Minocycline FDA Label
3 Emerging disease-modifying therapies for the treatment of motor neuron disease/amyotropic lateral sclerosis. Expert Opin Emerg Drugs. 2007 May;12(2):229-52.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 064216.
6 Functional, biophysical, and structural bases for antibacterial activity of tigecycline. Antimicrob Agents Chemother. 2006 Jun;50(6):2156-66.
7 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
8 Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann Pharmacother. 1999 Sep;33(9):960-7.